Actelion spins out new firm as part of its acquisition by J&J; later named Idorsia, includes assets of Actelion's Vaxxilon division
As part of its $30bn cash acquisition by Johnson & Johnson, Actelion Ltd. is spinning out its drug discovery operations and early-stage clinical assets into a new Swiss biopharma company (R&D NewCo).
- Drug Discovery Tools
- Full Acquisition
- Includes Earnout
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com